Roche Holding Valuation
Is ROG N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ROG N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ROG N (MX$5833.34) is trading below our estimate of fair value (MX$12887.08)
Significantly Below Fair Value: ROG N is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ROG N?
Key metric: As ROG N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ROG N's PE Ratio? | |
|---|---|
| PE Ratio | 19x |
| Earnings | CHF 10.62b |
| Market Cap | CHF 204.09b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.9x |
| Enterprise Value/EBITDA | 11.2x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does ROG N's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 21.3x | ||
LAB B Genomma Lab Internacional. de | 15x | 19.8% | Mex$24.9b |
NOVN Novartis | 17.6x | 7.0% | CHF 183.8b |
MRK Merck | 21.1x | 15.6% | US$250.9b |
AZN AstraZeneca | 31.4x | 18.4% | UK£162.4b |
ROG N Roche Holding | 19x | 11.1% | Mex$204.1b |
Price-To-Earnings vs Peers: ROG N is good value based on its Price-To-Earnings Ratio (19x) compared to the peer average (21.3x).
Price to Earnings Ratio vs Industry
How does ROG N's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 27 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 27 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: ROG N is good value based on its Price-To-Earnings Ratio (19x) compared to the Global Pharmaceuticals industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is ROG N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 19x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ROG N's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$7,073.49 0% | 17.1% | Mex$10,241.90 | Mex$5,120.95 | n/a | 17 |
| Nov ’25 | Mex$6,476.15 | Mex$7,002.26 +8.1% | 17.0% | Mex$10,096.59 | Mex$5,071.35 | n/a | 17 |
| Oct ’25 | n/a | Mex$6,999.58 0% | 17.3% | Mex$10,198.07 | Mex$5,099.03 | n/a | 18 |
| Sep ’25 | Mex$6,563.60 | Mex$6,922.20 +5.5% | 17.1% | Mex$10,302.58 | Mex$5,151.29 | n/a | 19 |
| Aug ’25 | n/a | Mex$6,107.65 0% | 17.1% | Mex$9,339.67 | Mex$4,669.84 | n/a | 19 |
| Jul ’25 | Mex$5,128.00 | Mex$5,665.45 +10.5% | 20.4% | Mex$8,704.22 | Mex$4,270.76 | n/a | 19 |
| Jun ’25 | Mex$4,383.24 | Mex$5,220.95 +19.1% | 20.5% | Mex$8,051.72 | Mex$3,950.61 | n/a | 19 |
| May ’25 | Mex$4,000.08 | Mex$5,181.09 +29.5% | 20.6% | Mex$7,924.38 | Mex$3,888.13 | n/a | 18 |
| Apr ’25 | Mex$4,107.16 | Mex$5,171.88 +25.9% | 19.9% | Mex$7,796.13 | Mex$3,861.29 | n/a | 18 |
| Mar ’25 | Mex$4,495.00 | Mex$5,495.29 +22.3% | 19.3% | Mex$8,234.84 | Mex$4,078.58 | n/a | 18 |
| Feb ’25 | Mex$4,639.74 | Mex$5,936.48 +27.9% | 19.5% | Mex$8,964.48 | Mex$4,482.24 | n/a | 18 |
| Jan ’25 | n/a | Mex$6,078.83 0% | 19.6% | Mex$9,342.75 | Mex$4,453.64 | n/a | 19 |
| Dec ’24 | Mex$4,715.21 | Mex$6,089.39 +29.1% | 18.7% | Mex$9,336.84 | Mex$4,450.83 | n/a | 18 |
| Nov ’24 | Mex$4,696.27 | Mex$6,101.64 +29.9% | 18.7% | Mex$9,355.63 | Mex$4,459.78 | Mex$6,476.15 | 18 |
| Oct ’24 | n/a | Mex$5,980.98 0% | 17.2% | Mex$9,120.94 | Mex$4,770.37 | n/a | 18 |
| Sep ’24 | Mex$4,858.03 | Mex$6,198.57 +27.6% | 16.6% | Mex$9,212.74 | Mex$4,825.75 | Mex$6,563.60 | 19 |
| Aug ’24 | Mex$5,197.49 | Mex$6,295.08 +21.1% | 16.1% | Mex$9,198.33 | Mex$4,816.08 | n/a | 20 |
| Jul ’24 | Mex$5,263.59 | Mex$6,238.72 +18.5% | 16.0% | Mex$8,681.62 | Mex$4,754.76 | Mex$5,128.00 | 19 |
| Jun ’24 | Mex$5,565.11 | Mex$6,497.74 +16.8% | 15.9% | Mex$8,890.06 | Mex$4,868.92 | Mex$4,383.24 | 21 |
| May ’24 | n/a | Mex$6,748.93 0% | 15.3% | Mex$9,052.41 | Mex$5,029.12 | Mex$4,000.08 | 22 |
| Apr ’24 | Mex$5,167.94 | Mex$6,892.12 +33.4% | 15.3% | Mex$9,013.76 | Mex$5,007.64 | Mex$4,107.16 | 23 |
| Mar ’24 | Mex$5,321.44 | Mex$6,738.62 +26.6% | 13.9% | Mex$8,667.20 | Mex$4,815.11 | Mex$4,495.00 | 24 |
| Feb ’24 | Mex$5,830.34 | Mex$7,199.39 +23.5% | 13.3% | Mex$9,432.57 | Mex$5,375.55 | Mex$4,639.74 | 24 |
| Jan ’24 | Mex$6,227.14 | Mex$7,889.46 +26.7% | 11.0% | Mex$9,567.45 | Mex$6,378.30 | n/a | 24 |
| Dec ’23 | Mex$6,319.05 | Mex$7,671.03 +21.4% | 10.6% | Mex$9,234.13 | Mex$6,156.09 | Mex$4,715.21 | 24 |
| Nov ’23 | Mex$6,295.93 | Mex$7,495.51 +19.1% | 10.5% | Mex$8,987.63 | Mex$5,991.75 | Mex$4,696.27 | 24 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Novartis
CHF 187.3b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
NOVN N
CHF 2,236.00
7D
0%
1Y
n/a